TSHR CRE-Luc HEK293
CBP71485
| I. Background | |
| 
				       G 蛋白偶聯(lián)受體(GPCR)是跨膜蛋白受體,其特征是配體數(shù)量可變,包括內(nèi)源性神 經(jīng)遞質(zhì)和激素,也包括外源性天然和人工化合物。激動(dòng)劑與受體結(jié)合后會(huì)觸發(fā)信號通路的 激活;而拮抗劑則會(huì)阻礙激動(dòng)劑介導(dǎo)的受體激活。反向激動(dòng)劑除像拮抗劑一樣干擾激動(dòng)劑 外,還會(huì)抑制受體的組成活性。  | 
		|
| II. Description | |
| 
				 TSHR CRE-Luc HEK293 報(bào)告基因藥靶模型很好的模擬了體內(nèi) TSHR 的信號轉(zhuǎn)導(dǎo)過程,原理見下圖所示。  | 
		|
  Figure 1. TSHR CRE-Luc HEK293細(xì)胞模型原理圖 
			 | 
		|
| III. Introduction | |
| Expressed gene: | TSHR | 
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) | 
| Freeze Medium: | 90% FBS+10% DMSO | 
| Culture Medium: | DMEM+10%FBS+2 μg/ml puromycin+200 μg/ml hygromycin | 
| Mycoplasma Testing: | Negative | 
| Storage: | Liquid nitrogen | 
| Application(s): | Functional assay for TSHR | 
| Transducer: | Gs | 
IV. Representative Data![]() Figure 2. Recombinant TSHR CRE-Luc HEK293 stably expressing TSHR. ![]() Figure 3. Dose Response of Agonists in TSHR CRE-Luc HEK293(C31).  | 
		|
            
 
